Reilly Kevin C 4

What Happened

• Kevin C. Reilly, a director of Kestra Medical Technologies, Ltd. (KMTS), was granted 8,300 restricted stock units (RSUs) on March 11, 2026. The filing reports this as an Award/Grant (transaction code A). No purchase price or total value is shown in the filing (price listed as N/A).

Key Details

• Transaction date: March 11, 2026 (Form 4 filed March 12, 2026 — within the typical two-business-day reporting window).
• Grant: 8,300 RSUs; acquisition price: N/A (award).
• Shares owned after transaction: not specified in the filing.
• Footnote: Each RSU converts to one common share; the RSUs vest on September 4, 2026, subject to the reporting person’s continued service through that date.

Context

• RSUs are a form of equity compensation that convert to actual shares only upon vesting; this grant does not represent an immediate open-market purchase or sale. Such awards are common for executive and board compensation and do not by themselves indicate near-term buying or selling intentions.